JP2018536390A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536390A5
JP2018536390A5 JP2018517357A JP2018517357A JP2018536390A5 JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5 JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5
Authority
JP
Japan
Prior art keywords
sequence
eukaryotic cell
seq
trc1
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517357A
Other languages
English (en)
Japanese (ja)
Other versions
JP6929837B2 (ja
JP2018536390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055472 external-priority patent/WO2017062439A1/en
Publication of JP2018536390A publication Critical patent/JP2018536390A/ja
Publication of JP2018536390A5 publication Critical patent/JP2018536390A5/ja
Priority to JP2021131109A priority Critical patent/JP2022000019A/ja
Application granted granted Critical
Publication of JP6929837B2 publication Critical patent/JP6929837B2/ja
Priority to JP2023133416A priority patent/JP2023175698A/ja
Priority to JP2025092415A priority patent/JP2025143265A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517357A 2015-10-05 2016-10-05 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ Active JP6929837B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021131109A JP2022000019A (ja) 2015-10-05 2021-08-11 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2023133416A JP2023175698A (ja) 2015-10-05 2023-08-18 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2025092415A JP2025143265A (ja) 2015-10-05 2025-06-03 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562237382P 2015-10-05 2015-10-05
US62/237,382 2015-10-05
US201662297445P 2016-02-19 2016-02-19
US62/297,445 2016-02-19
PCT/US2016/055472 WO2017062439A1 (en) 2015-10-05 2016-10-05 Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131109A Division JP2022000019A (ja) 2015-10-05 2021-08-11 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2018536390A JP2018536390A (ja) 2018-12-13
JP2018536390A5 true JP2018536390A5 (enExample) 2019-11-14
JP6929837B2 JP6929837B2 (ja) 2021-09-15

Family

ID=57184827

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018517357A Active JP6929837B2 (ja) 2015-10-05 2016-10-05 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2021131109A Pending JP2022000019A (ja) 2015-10-05 2021-08-11 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2023133416A Pending JP2023175698A (ja) 2015-10-05 2023-08-18 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2025092415A Pending JP2025143265A (ja) 2015-10-05 2025-06-03 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021131109A Pending JP2022000019A (ja) 2015-10-05 2021-08-11 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2023133416A Pending JP2023175698A (ja) 2015-10-05 2023-08-18 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
JP2025092415A Pending JP2025143265A (ja) 2015-10-05 2025-06-03 ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ

Country Status (8)

Country Link
US (4) US10799535B2 (enExample)
EP (3) EP3680329B1 (enExample)
JP (4) JP6929837B2 (enExample)
AU (4) AU2016333886B2 (enExample)
CA (1) CA3001008A1 (enExample)
DK (2) DK3680329T3 (enExample)
ES (2) ES2883116T3 (enExample)
WO (1) WO2017062439A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4108255A1 (en) * 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
ES2883116T3 (es) * 2015-10-05 2021-12-07 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
CA3020330A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
ES3039670T3 (en) 2016-04-15 2025-10-23 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ,インク. T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
US20200239544A1 (en) * 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2019084552A1 (en) * 2017-10-27 2019-05-02 The Regents Of The University Of California TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS
RU2020116585A (ru) 2017-10-30 2021-12-01 Пэкт Фарма, Инк. Редактирование гена первичных клеток
US20200299658A1 (en) * 2017-11-01 2020-09-24 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
SG11202009761YA (en) 2018-04-02 2020-10-29 Pact Pharma Inc Peptide-mhc compacts
JP7304888B2 (ja) * 2018-04-12 2023-07-07 プレシジョン バイオサイエンシズ,インク. ヒトt細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ
WO2020106633A1 (en) * 2018-11-19 2020-05-28 Altius Institute For Biomedical Sciences Compositions and methods for detection of cleavage of genomic dna by a nuclease
CN113661243A (zh) * 2019-02-08 2021-11-16 H·李莫菲特癌症中心和研究机构有限公司 消除Sirt2的嵌合T细胞
MX2021009640A (es) 2019-02-12 2021-10-13 Pact Pharma Inc Composiciones y metodos para la identificacion de celulas t especificas de antigenos.
WO2020205759A1 (en) * 2019-03-29 2020-10-08 Pact Pharma, Inc. Personalized neoantigen-specific adoptive cell therapies
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
KR20220005555A (ko) 2019-05-07 2022-01-13 프리시젼 바이오사이언시스 인코포레이티드 인식 서열에 대한 조작된 메가뉴클레아제의 최적화
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
EP4025597A2 (en) * 2019-09-06 2022-07-13 Avectas Limited Engineering of immune cells for ex vivo cell therapy applications
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
KR20220094217A (ko) * 2019-11-05 2022-07-05 론자 워커스빌 아이엔씨. 동종이계 t-세포 및 이의 생산 방법
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
EP4736838A2 (en) * 2021-04-22 2026-05-06 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
CA3246480A1 (en) 2022-01-07 2023-07-13 Precision Biosciences, Inc. POLYNUCLEOTIDES OPTIMIZED FOR PROTEIN EXPRESSION
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
US20100151556A1 (en) 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
WO2010015899A2 (en) 2008-08-04 2010-02-11 Cellectis Novel method to generate meganucleases with altered characteristics
EP2215223B1 (en) * 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA3157027A1 (en) * 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
ES2713529T3 (es) 2011-06-01 2019-05-22 Prec Biosciences Inc Procedimientos y productos para la producción de líneas celulares de mamífero modificadas con transgenes amplificados
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP4541818A3 (en) 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
KR20140019635A (ko) 2012-08-06 2014-02-17 엘지이노텍 주식회사 발광 소자 및 발광 소자 패키지
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2975942B1 (en) 2013-03-21 2018-08-08 Sangamo Therapeutics, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
DK3309248T3 (da) 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
US10006052B2 (en) 2013-05-31 2018-06-26 Cellectis Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof
ES2716867T3 (es) 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
CN110713995B (zh) 2013-10-17 2023-08-01 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
AU2015216875B2 (en) 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
AU2015229299A1 (en) * 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
GB2540694A (en) 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
AU2016243583B2 (en) 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
GB2557123B (en) 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy
EP4108255A1 (en) 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
ES2883116T3 (es) * 2015-10-05 2021-12-07 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
CA3009637A1 (en) 2015-12-23 2017-06-29 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
AU2017230011A1 (en) 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
ES3039670T3 (en) 2016-04-15 2025-10-23 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ,インク. T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP7304888B2 (ja) 2018-04-12 2023-07-07 プレシジョン バイオサイエンシズ,インク. ヒトt細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ

Similar Documents

Publication Publication Date Title
JP2018535663A5 (enExample)
US11268065B2 (en) Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
US20220152112A1 (en) Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CA3151690A1 (en) Genetically-edited immune cells and methods of therapy
KR20220016475A (ko) 변형된 tgfbr2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
JP2021520800A5 (enExample)
CN110139675A (zh) 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法
KR20230157387A (ko) Cas 효소를 이용한 다중 편집
HK40087901A (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
HK40043947A (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
HK40043947B (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
HK1259673A1 (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene